Kornimate/medical-research-clean huggingface dataset:
effects of bodily illusion and tdcs on sci-related neuropathic pain

Conditions: Neuropathic Pain

Summary: the purpose of this study is to evaluate the effect of a combination of two procedures: (1) bodily illusion (bi) and (2) transcranial direct electrical stimulation (tdcs) on neuropathic pain.


Eligibility criteria:
inclusion criteria: 1. participants will be men or women, 18-70 years of age, with an incomplete cervical traumatic sci. 2. participants must have experienced neuropathic pain for a minimum of six months. they must have neuropathic pain in the moderate to severe category, which will be defined as a score of at least 4 on a numeric rating scale (nrs); (range of 0 to 10). 3. participants must be willing and able to sign informed consent exclusion criteria: 1. major psychiatric disease/disorder (self-reported) 2. a significant neurological trauma besides sci 3. a recent (one-year) history of alcohol or drug abuse (selfreported) 4. any other medical conditions in which transcranial dcs is relatively contraindicated, such as pregnancy, epilepsy and/or seizures
efficacy and safety of alirocumab (sar236553/regn727) versus ezetimibe in patients with hypercholesterolemia

Conditions: Hypercholesterolemia

Summary: alirocumab (sar236553/regn727) is a fully human monoclonal antibody that binds pcsk9 (proprotein convertase subtilisin/kexin type 9). primary objective of the study: to demonstrate the reduction of low-density lipoprotein cholesterol (ldl-c) by alirocumab in comparison with ezetimibe after 24 weeks of treatment in participants with hypercholesterolemia. secondary objectives: * to evaluate the effect of alirocumab in comparison with ezetimibe on ldl-c at other time points * to evaluate the effect of alirocumab on other lipid parameters * to evaluate the safety and tolerability of alirocumab

the maximum study duration was 34 weeks per participant, including a 24-week randomized treatment period.

Eligibility criteria:
inclusion criteria: * participants with hypercholesterolemia exclusion criteria: * age \< 18 or legal age of adulthood, whichever was greater * ldl-c \ 190 mg/dl (\> 4.9 mmol/l) * fasting serum triglycerides (tg) \> 400 mg/dl (\> 4.52 mmol/l) * known history of homozygous or heterozygous familial hypercholesterolemia the above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
empowered with movement to prevent obesity and weight regain

Conditions: Obesity; Weight Loss; Sedentary Lifestyle

Summary: this study will help determine the appropriate type, amount and intensity of physical activity most beneficial for preventing weight regain after weight loss in older adults.

the investigators will use a 3-group design in 180 older (65-85 years), obese (bmi=30-45 kg/m2), sedentary men and women, all of whom will undergo a 9-month weight loss (wl) intervention (6-mo intensive phase and 3-mo reduced contact phase), followed by a 9-month self-managed follow-up phase with minimal contact, to test our overall hypothesis that intervening on sedentary behavior (sitless) will enhance long-term weight loss in this age group. the diet element of the intervention is identical across groups, but groups differ by activity intervention: 1) structured, moderate-intensity, aerobic exercise (ex) (wl+ex); 2) intervening on sb throughout the day (wl+sitless); or 3) (wl+ex+sitless).

Eligibility criteria:
inclusion criteria: * 65-85 years * bmi=30-45 kg/m2 * weight stable-no loss or gain (±5%) in past 6 mo * sedentary * no contraindication for safe and optimal participation in exercise training * approved for participation by medical director * willing to provide informed consent * agree to all study procedures and assessments * able to provide own transportation to study visits and intervention exclusion criteria: * dependent on cane or walker * reported unintentional or intentional weight loss or gain of \>5% in past 6 mo participation in regular resistance training and/or \> 20 mins/day of aerobic exercise in past 6 months * cognitive impairment (moca score \<22) * low bone density (t-score \< -2.3 on hip or spine scan) * severe arthritis, or other musculoskeletal disorder * joint replacement or other orthopedic surgery in past 6 mos * joint replacement or other orthopedic surgery planned in next 2 years * uncontrolled resting hypertension (\>160/90 mmhg); * current or recent past (within 1 year) severe symptomatic heart disease, uncontrolled angina, stroke, chronic respiratory disease other than asthma or copd, any disease requiring oxygen use, neurological or hematological disease; cancer requiring treatment in past year, except non-melanoma skin cancers * serious conduction disorder, new q waves or st-segment depression (\>3 mm), or uncontrolled arrhythmia * room air spo2 (oxygen saturation) at rest or with exercise qualifying for supplementary oxygen (spo2≤88%) * abnormal kidney or liver function (2x upper limit of normal); * egfr \<45 ml/min/1.73m2 * anemia (hb\<13 g/dl in men/ \<12 g/dl in women); * uncontrolled diabetes (fasting glucose \>140 mg/dl); * deficient levels of vitamin d (25 hydroxyvitamin d level \< 20 ng/ml) in those not taking a vitamin d supplement; * smoker (no nicotine in past yr) * no heavy alcohol use (\>14 drinks/week) * unstable severe depression * regular use of: growth hormones, oral steroids, weight loss medications or prescription osteoporosis meds * current participation in other research study
bortezomib plus chop every 2 weeks for advanced stage dlbcl

Conditions: Lymphoma, Large-Cell, Diffuse; Lymphoma, B-Cell

Summary: diffuse large b-cell lymphoma is a most prevalent non-hodgkin's lymphoma. recently the clinical results have been improved with new drugs and new modalities such as cyclophosphamide, doxorubicin, vincristine, and prednisone (chop) every 2 weeks. bortezomib is well known to be effective for multiple myeloma and has been being tried for other malignancies including lymphoma. the investigators will incorporate bortezomib to chop every 2 weeks to further improve the clinical efficacy in diffuse large b-cell lymphoma.

intended number of patients: 63 patients in total * phase i: 9 patients for 3 levels * phase ii: 50 patients plus 3 patient from phase i at mtd level * plus 4 patients: considering 5% follow-up loss rate study design and methodology: for phase i, 9 patients; 3 levels of bortezomib (1.0, 1.3 and 1.6 mg/m2), 3 patients at each dose level. if escalation of bortezomib beyond 1.0 mg/m2 is not possible, the trial will be stopped. for phase ii, 53 patients (3 from phase i at mtd level); reject when complete response rate equal or less than 12/19 or 37/53 by simon two-stage optimal phase ii design. treatments: * bortezomib: for phase i, 3 dose levels (1.0, 1.3 or 1.6 mg/m2), days 1 and 4, every 2 weeks. for phase ii, suggested dose of bortezomib through phase i, days 1 and 4, every 2 weeks. * chop2: cyclophosphamide 750mg/ m2 day 1, vincristine 1.4 mg/ m2 (max. 2 mg) day 1, doxorubicin 50 mg/ m2 day 1, prednisolone 100 mg days 1-5, every 2 weeks. * g-csf: lenograstim 5 microgram/kg subcutaneously days 4-13 every 2 weeks.

Eligibility criteria:
inclusion criteria: * histologically confirmed dlbcl * age 70 years or less * previously untreated * performance status: ecog 0-2 * advanced stage: stage iii, iv, or non-contiguous stage ii * measurable disease: 1 cm or more by spiral ct * normal liver function exclusion criteria: * platelet count less than 75,000/microl within 14 days before enrollment. * absolute neutrophil count of less than 1,500/microll within 14 days before enrollment. * cr more than 2.0 mg/dl and/or calculated or measured creatinine clearance less than 50 ml/min within 14 days before enrollment. * peripheral neuropathy of grade 2 or worse within 14 days before enrollment. * hypersensitivity to bortezomib, boron or mannitol. * female subject is pregnant or breast-feeding. * other investigational drugs with 14 days before enrollment * serious medical or psychiatric illness likely to interfere with participation in this clinical study. * uncontrolled or severe cardiovascular disease, including mi within 6 months of enrolment, new york heart association (nyha) class iii or iv heart failure, uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis

Keywords: diffuse large b-cell lymphoma bortezomib chop lenograstim
a postoperative sore throat after lumbar spine surgery in the prone position

Conditions: Post Operative Sore Throat

Summary: this study was performed to compare the effect of dexmedetomidine and remifentanil on the incidence and severity of postoperative sore throat in patients undergoing spinal surgery in the prone position who are at risk of developing postoperative sore throat.


Eligibility criteria:
inclusion criteria: 1. american society of anesthesiologists (asa) physical status classification i and ii 2. undergoing lumbar spine surgery in prone position exclusion criteria: 1. pre-existing sore throat, hoarseness, or upper respiratory tract infection 2. allergy to the study drugs 3. anticipated difficult airways 4. more than two attempts at intubation
efficacy and safety of a fixed or a flexible supplementary insulin therapy in type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe. this trial aims for a comparison of the efficacy and safety of insulin aspart, given in a fixed or in a flexible supplementary insulin therapy, with or without insulin detemir plus metformin, if needed, in subjects with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * type 2 diabetes for more than 6 months * treatment with 1 or more oral anti-diabetic drugs or insulin, or a combination of these for more than 3 months * body mass index (bmi) less than or equal to 40 kg/m2 * hba1c 7.0-11.0% exclusion criteria: * treatment with short acting insulin(s) for longer than 10 days * current treatment with tzds. a tzd medication must be stopped at least 14 days before the randomization * proliferative retinopathy or maculopathy requiring acute or laser treatment within the last 6 months
naglazyme after allo transplant for maroteaux-lamy syndrome

Conditions: Maroteaux-Lamy Syndrome

Summary: this is a single center study in which naglazyme® will be given weekly for two years in patients with maroteaux-lamy syndrome, also known as mucopolysaccharide vi (mps vi), who have previously been treated with an allogeneic transplant.


Eligibility criteria:
inclusion criteria: * mucopolysaccharidosis type vi (mps vi, maroteaux-lamy syndrome) treated with a prior allogeneic transplant \>2 years previously * persons currently receiving naglazyme may be accepted into the study * age \> 2 years * \>10% engrafted based on most recent testing * willing to commit to traveling to the university of minnesota every 6 months * written informed consent with parent/guardian consent for children \< 18 years of age or persons unable to consent with minor assent if appropriate exclusion criteria: * history of cardiac or pulmonary insufficiency or those requiring continuous supplemental oxygen * pregnant or breastfeeding * any condition that, in the view of the investigator, places the patient at high risk of poor treatment compliance or of not completing the study

Keywords: maroteaux-lamy syndrome mucopolysaccharide vi mps vi
intratumorally-administered topotecan using convection-enhanced delivery in patients with grade iii/ iv glioma

Conditions: Glioma of Brain

Summary: the purpose of this study is to determine if treatment with topotecan by an alternative method, delivering topotecan directly into brain tumors, is safe and well tolerated.


Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of supratentorial who grade iii or iv glioma (high grade glioma) that has undergone surgical biopsy or resection followed by adjuvant chemoradiotherapy, that has evidence of recurrence or progression based on imaging studies and a stereotactic biopsy is indicated for confirmation of recurrence/progression. * 18 years of age or older * karnofsky performance status 70-100; * mri demonstration of a stereotactically accessible enhancing or predominantly non- enhancing mass that does not require resection to relieve clinically significant mass effect; * participant understands the procedures and agrees to comply with the study requirements by providing written informed consent * adequate organ function as indicated in protocol exclusion criteria: * participant is mentally or legally incapacitated at the time of the study; * known hiv(+) or has been diagnosed with aids * participation in another investigational drug study in the prior 4 weeks * positive pregnancy test in a female * patient, in the opinion of the investigator, is likely to be poorly compliant. * diffuse subependymal or cerebral spinal fluid (csf) disease * tumors involving the cerebellum * tumor enhancement involving both hemispheres * active infection requiring treatment * unexplained febrile illness * radiation or chemotherapy within 4 weeks of enrollment * systemic diseases associated with unacceptable anesthesia or operative risk * inability to undergo magnetic resonance imaging (mri)

Keywords: glioma brain tumor high grade glioma
electromyography evaluation of subscapularis function after total shoulder arthroplasty

Conditions: Osteoarthritis

Summary: the primary objective is to document function of the structurally intact subscapularis after total shoulder arthroplasty by using electromyography. structural integrity of the subscapularis will be confirmed using ultrasound. the secondary objective is to determine the diagnostic accuracy of the belly compression and lift off tests in evaluating the integrity and function of the subscapularis when compared to the ultrasound and electromyography (emg). this will be accomplished by enrolling and evaluating patients with a primary diagnosis of osteoarthritis who have had a total shoulder replacement preformed by the pi from september 2003 through december 2007.

the functional status of the subscapularis following total shoulder arthroplasty has not been well documented. there is evidence of loss of subscapularis function shown through physical exam in up to 2/3 of patients following total shoulder arthroplasty. \[1\] multiple techniques for subscapularis repair have been demonstrated with varying degrees of post operative function, ranging from 11-66% abnormal function on physical exam. \[1-3\] the belly compression test and the lift off test, which are the main physical exam tests used for evaluation following surgery, are of questionable reliability as indicators of the functionality of the subscapularis. \[4,5\] through comparing ultrasound evidence of an intact subscapularis to physical exam findings it has been recognized that the belly compression test has low sensitivity and specificity for subscapularis integrity. \[5\] internal rotation is often limited in many postoperative total shoulder patients, which could lead to false positive results. this questions the validity of the outcomes of the studies in which the standard of testing function was through exam. ultrasound is a reliable exam for illustration of structural damage to the subscapularis tendon but additional testing is needed to evaluate the function of the structurally intact subscapularis. \[5,6\] irreparable changes in the muscle function or nerve denervation could also result in false positive belly compression and lift off tests. the ability to accurately determine the functionality of the subscapularis following total shoulder replacement is imperative to clinic management. although studies have shown functional abnormalities through physical exam, none have documented the functional status of the subscapularis using objective means such as emg.

Eligibility criteria:
inclusion criteria: * age \>45yrs; * primary diagnosis of osteoarthritis of the shoulder * total shoulder replacement performed by dr. armstrong between september 2003 through december 2007. exclusion criteria: * known contraindications to ultrasound and/or emg * inability to provide informed consent * history of recent trauma to the shoulder * typical shoulder pain * other suspected shoulder pathology (i.e. tumor, infection) * pregnancy * bilateral total shoulder arthroplasty

Keywords: total shoulder arthroplasty osteoarthritis
clinical investigation of the cardioprotective effect of early administration of sglt2 in patients presented with ami

Conditions: Myocardial Infarction

Summary: this study aims to investigate the effect of early administration of dapa during ischemia and before ppci on infarct size, reperfusion injury-related myocardial damage, cardioprotection from hf, and renoprotection from aki in patients with ami.

dapa was approved for hf patients, but there is no sufficient data about its efficacy on patients with ami and if it can protect from the development of hf after ami. the investigators aim to investigate the effect of dapa on patients who presented with ami when administered as early as possible before ppci and to be continued for three months after there. the effect of dapa on infarct size, cardiac biomarkers will be assessed during the follow-up period

Eligibility criteria:
inclusion criteria: 1. patients with st-elevation myocardial infarction (stemi). 2. stemi was defined according to the fourth universal definition of ami. 3. 18 - 80 years of age. 4. diabetics or non-diabetics. 5. egfr \> 45 ml/min/1.73m2. 6. blood pressure before first drug dosing \>110/70 mmhg. exclusion criteria: 1. cardiogenic shock. 2. hypoglycemia. 3. history of diabetic ketoacidosis. 4. genital and urinary infections. 5. history of ami. 6. stent thrombosis. 7. previous coronary artery bypass surgery. 8. severe hepatic insufficiency. 9. advanced cancer patients. 10. blood ph \< 7.32. 11. known allergy to sglt-2 inhibitors. 12. hemodynamic instability. 13. females of childbearing potential without adequate contraceptive methods. 14. patients currently on or have received any sglt-2 inhibitors.
novel low cost bubble cpap as an alternative respiratory support in low resource setting

Conditions: Premature; Respiratory Distress Syndrome in Premature Infant

Summary: this is a single-blind randomized controlled trial done in a level iii neonatal intensive care unit. preterm newborns with rds were randomized to receive oxygen therapy through bubble cpap vs ventilator-derived cpap. differences in arterial blood gases, oxygen saturation, number of surfactant and cpap failure rate between study groups were analyzed.

background and objective: respiratory distress syndrome (rds) among premature infants is one of the major causes of neonatal death. the use of continuous positive airway pressure (cpap) has become a standard of care for preterm newborns with rds. in countries faced with the challenge of improving neonatal care, cost-effective innovations for respiratory support are a promising intervention. this study determined the efficacy of a low-cost bubble cpap as an alternative non-invasive oxygen therapy for newborn infants with rds. methods: this is a single-blind randomized controlled trial done in a level iii neonatal intensive care unit. preterm newborns with rds were randomized to receive oxygen therapy through bubble cpap vs ventilator-derived cpap. differences in arterial blood gases, oxygen saturation, number of surfactant and cpap failure rate between study groups were analyzed.

Eligibility criteria:
inclusion criteria: * included are preterm neonates less than 36 weeks (who definition) * admitted at nicu * apgar scores of \> 7 in the 1st and 5th minute of life * in respiratory distress at birth, * radiologic findings of rds * respiratory severity score (rss) or downe's score \> 4 at 10-15 minutes after hooking to cpap * requiring cpap or more than 40% fio2 exclusion criteria: * infants requiring neonatal resuscitation such as bag mask ventilation, chest compression or intubation at birth * with comorbidities such as facial anomalies, tracheoesophageal fistulas, congenital heart disease, and other congenital anomalies which may interfere with the interface of both devices.
3dv+tps software outlines the radiotherapy of nasopharyngeal carcinoma

Conditions: Radiotherapy; Nasopharyngeal Carcinoma

Summary: comparing the accuracy and speed of 3dv+tps software with imported tps and domestic tps to outline the contours of crisis organs, it is proved that 3dv+tps has superiority compared with domestic tps, and it has non-inferiority compared with imported tps, indicating that the software can improve contour sketching accuracy. and speed, reduce the burden on doctors, improve medical efficiency.

comparing the accuracy and speed difference between 3dv+tps software and imported tps and domestic tps to outline the contours of crisis organs, the selected organs are: bilateral eyeballs, bilateral crystals, bilateral optic nerves, bilateral parotid glands, oral cavity, spinal cord, brainstem, the brain has a total of 12 organs; verify that 3dv+tps is superior to domestic tps, and has non-inferiority compared with imported tps, ming software can improve the accuracy and speed of contour sketching, reduce the burden on doctors, and improve medical efficiency.

Eligibility criteria:
inclusion criteria: 1. it is diagnosed as nasopharyngeal carcinoma by histopathological examination, and there is no tumor invasion in the organs that need to be assessed; 2. age 18-70 years old; 3. there is nasopharynx localization enhanced ct, nasopharynx enhanced mri. exclusion criteria: 1. patient information is incomplete; no age, gender, mri, height, radiotherapy location ct; 2. the organs at risk that need to be assessed are invaded by the tumor; 3. any reason cannot be combined with the research or the researcher believes that it is not suitable for inclusion in this test.